STOCK TITAN

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

BioCardia, Inc. will host a conference call on May 14, 2024, to discuss its financial results for the first quarter of 2024 and provide a corporate update. The company specializes in developing therapeutics for cardiovascular and pulmonary diseases.

Positive
  • None.
Negative
  • None.

SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the the three months ended March 31, 2024 and provide a corporate update by conference call on Tuesday, May 14, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10189148/fc87734564. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=TeAMFuE4.

A webcast replay of the call will be available approximately one hour after the end of the call through August 14, 2024 at the above links. To access the replay internationally, please use the link https://services.choruscall.com/ccforms/replay.html. The telephonic replay of the call will be available through May 28, 2024 and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 5376275.

About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. BioCardia also works with partners to provide its proprietary Helix transendocardial biotherapeutic delivery system, as well as technology and services for the development and commercialization of partners’ therapeutic agents. For more information visit www.biocardia.com.

 


FAQ

When will BioCardia host the conference call?

BioCardia will host the conference call on May 14, 2024.

What will be discussed during the conference call?

BioCardia will discuss its financial results for the first quarter of 2024 and provide a corporate update.

What does BioCardia specialize in?

BioCardia specializes in developing therapeutics for cardiovascular and pulmonary diseases.

BioCardia, Inc.

NASDAQ:BCDA

BCDA Rankings

BCDA Latest News

BCDA Stock Data

5.75M
1.82M
29.56%
7.13%
4.23%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SUNNYVALE